This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Tony De Fougerolles, PhD
CEO at Evox Therapeutics Limited


joined Evox as CEO in late 2017 and oversees the management of the company. Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies).

Prior to joining Evox, Tony was CSO of Ablynx from 2013-2017 where he served on the executive management team and led the company’s non-clinical R&D operations. During his time at Ablynx, Tony helped advance the lead clinical assets through Phase 2 and 3, increased the pipeline of single domain antibody (Nanobody) drugs by over 3-fold to over 45 programs, and was instrumental in establishing new large BD deals with Merck & Co., Novo Nordisk, and Sanofi.

Prior to Ablynx, Tony was founding CSO at Moderna Therapeutics where he led the science, helping to grow the company from a start-up of half a dozen people to an established biotech with over 75 people and a $240M upfront pre-clinical deal with Astra Zeneca. Previously, Tony was CSO at Tolerx Inc working on clinical stage antibody-based immunomodulatory and immune-oncology drugs, and prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research from 2003-2010, where he played a key role in growing the company from a start-up, advancing the pipeline, and in developing the RNAi delivery systems now either approved or used in late-stage clinical trials. He also served as a Principal Scientist at Biogen from 1998-2003 where he worked on several antibody-based inflammation programs.

Tony has been Principal Investigator on numerous grant awards totaling over $80M and was named by Pharmaceutical Executive magazine as an “Emerging Pharma Leader” in 2009. Tony has over 60 scientific publications and is an inventor on 90 issued U.S. patents and a similar number of patents in other localities. He earned his Ph.D. in Immunology from Harvard University.